Abstract

Bisphosphonates are now the most widely used drugs for osteoporosis. Three bisphosphonates are available in Japan, i.e. etidronate, alendronate and risedronate. In these bisphosphonates, risedronate as the third-generation bisphosphonate was shown in many RCTs to decrease bone resorption biomarkers and to increase BMD. The relative risk of new vertebral fractures and non-vertebral fractures was reduced by about 50% or more. Risedronate is one of the most effective agents for prevention of osteoporotic fractures. Once-weekly treatment with 17.5 mg risedronate showed equivalent efficacy to once-daily treatment with 2.5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.